Tralokinumab
(Anti-human IL-13 mAb, human IgG4P-Kappa; CAT-354)
Catalog No.: PC-Ab1054Not For Human Use, Lab Use Only.
Tralokinumab (CAT-354) is an potent and selective IL-13-neutralizing IgG4 monoclonal antibody (mAb). Tralokinumab specifically binds with high affinity to IL-13, inhibiting its interaction with the IL-13 receptor and thereby neutralising the biological activity of the cytokine. Tralokinumab was approved for the treatment of moderate-to-severe atopic dermatitis..
Tralokinumab (CAT-354) is an potent and selective IL-13-neutralizing IgG4 monoclonal antibody (mAb). Tralokinumab specifically binds with high affinity to IL-13, inhibiting its interaction with the IL-13 receptor and thereby neutralising the biological activity of the cytokine. Tralokinumab was approved for the treatment of moderate-to-severe atopic dermatitis.
Physicochemical Properties
M.Wt
Formula
Human IgG4P-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
